Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Renal Cell | 17 | 2024 | 3217 | 1.900 |
Why?
|
Kidney Neoplasms | 17 | 2024 | 4312 | 1.710 |
Why?
|
Endogenous Retroviruses | 1 | 2022 | 111 | 0.740 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2023 | 2277 | 0.680 |
Why?
|
Peritoneal Dialysis | 1 | 2020 | 157 | 0.640 |
Why?
|
Neoplasms | 14 | 2024 | 22066 | 0.520 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2022 | 800 | 0.490 |
Why?
|
Immunoconjugates | 1 | 2022 | 949 | 0.460 |
Why?
|
Radiosurgery | 1 | 2023 | 1343 | 0.440 |
Why?
|
Antineoplastic Agents | 3 | 2021 | 13629 | 0.330 |
Why?
|
Urinary Bladder, Neurogenic | 2 | 2021 | 174 | 0.330 |
Why?
|
Pandemics | 5 | 2022 | 8621 | 0.310 |
Why?
|
Kidney Failure, Chronic | 1 | 2020 | 2469 | 0.290 |
Why?
|
Posture | 3 | 2020 | 954 | 0.290 |
Why?
|
Immunotherapy | 6 | 2024 | 4637 | 0.270 |
Why?
|
Healthcare Disparities | 1 | 2021 | 3381 | 0.250 |
Why?
|
Gait | 2 | 2020 | 812 | 0.240 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2024 | 102 | 0.220 |
Why?
|
Scoliosis | 2 | 2020 | 733 | 0.220 |
Why?
|
Spine | 2 | 2020 | 1111 | 0.210 |
Why?
|
Neoplasm Metastasis | 2 | 2024 | 4891 | 0.210 |
Why?
|
Walking | 2 | 2020 | 1190 | 0.210 |
Why?
|
HLA-A3 Antigen | 1 | 2021 | 34 | 0.200 |
Why?
|
Intermittent Urethral Catheterization | 1 | 2021 | 13 | 0.190 |
Why?
|
Africa, Northern | 1 | 2021 | 86 | 0.190 |
Why?
|
Bacteriuria | 1 | 2021 | 104 | 0.180 |
Why?
|
Warts | 1 | 2021 | 66 | 0.180 |
Why?
|
Lymphatic Diseases | 1 | 2022 | 319 | 0.180 |
Why?
|
Humans | 51 | 2024 | 760261 | 0.180 |
Why?
|
Middle East | 1 | 2021 | 230 | 0.180 |
Why?
|
Adrenergic beta-3 Receptor Agonists | 1 | 2019 | 14 | 0.180 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2022 | 259 | 0.170 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 317 | 0.170 |
Why?
|
Eye Neoplasms | 1 | 2020 | 306 | 0.160 |
Why?
|
Pelvis | 2 | 2020 | 743 | 0.160 |
Why?
|
Acetanilides | 1 | 2019 | 169 | 0.150 |
Why?
|
Epigenomics | 1 | 2024 | 936 | 0.150 |
Why?
|
Kyphosis | 1 | 2020 | 237 | 0.150 |
Why?
|
Liver Failure | 1 | 2018 | 249 | 0.140 |
Why?
|
Postural Balance | 1 | 2020 | 617 | 0.130 |
Why?
|
Urinary Tract Infections | 1 | 2021 | 817 | 0.120 |
Why?
|
Photochemotherapy | 1 | 2021 | 819 | 0.120 |
Why?
|
Drug Approval | 1 | 2021 | 816 | 0.110 |
Why?
|
Urban Population | 1 | 2022 | 2021 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1591 | 0.110 |
Why?
|
Melanoma | 2 | 2023 | 5695 | 0.110 |
Why?
|
Up-Regulation | 1 | 2022 | 4127 | 0.110 |
Why?
|
Renal Insufficiency | 1 | 2018 | 820 | 0.100 |
Why?
|
Androgen Antagonists | 1 | 2021 | 1439 | 0.100 |
Why?
|
Thiazoles | 1 | 2019 | 1509 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor A | 4 | 2023 | 3483 | 0.100 |
Why?
|
Carcinoma | 1 | 2023 | 2334 | 0.100 |
Why?
|
Rural Population | 1 | 2022 | 2267 | 0.090 |
Why?
|
Registries | 2 | 2024 | 8449 | 0.090 |
Why?
|
Venous Thromboembolism | 1 | 2023 | 1866 | 0.090 |
Why?
|
Respiratory Insufficiency | 1 | 2018 | 1228 | 0.090 |
Why?
|
Bone and Bones | 1 | 2020 | 2560 | 0.080 |
Why?
|
Imaging, Three-Dimensional | 2 | 2020 | 4044 | 0.080 |
Why?
|
Retrospective Studies | 12 | 2024 | 80301 | 0.080 |
Why?
|
Lebanon | 2 | 2021 | 245 | 0.080 |
Why?
|
Anilides | 2 | 2022 | 409 | 0.080 |
Why?
|
Patient Selection | 1 | 2021 | 4276 | 0.080 |
Why?
|
Papillomavirus Infections | 1 | 2021 | 1600 | 0.080 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 3696 | 0.080 |
Why?
|
Multiple Organ Failure | 2 | 2023 | 387 | 0.080 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 3159 | 0.070 |
Why?
|
Lung Neoplasms | 2 | 2022 | 13249 | 0.070 |
Why?
|
Nuclear Proteins | 1 | 2022 | 5793 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3215 | 0.070 |
Why?
|
Female | 17 | 2024 | 391011 | 0.070 |
Why?
|
Male | 16 | 2024 | 359413 | 0.070 |
Why?
|
Biomedical Research | 1 | 2022 | 3421 | 0.070 |
Why?
|
Breast Neoplasms | 2 | 2024 | 21065 | 0.070 |
Why?
|
Research Design | 1 | 2022 | 6181 | 0.070 |
Why?
|
Mass Screening | 1 | 2021 | 5422 | 0.060 |
Why?
|
Middle Aged | 13 | 2024 | 220175 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9196 | 0.060 |
Why?
|
DNA-Binding Proteins | 1 | 2022 | 9590 | 0.060 |
Why?
|
Aged | 11 | 2024 | 168995 | 0.060 |
Why?
|
Hospitalization | 1 | 2024 | 10761 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5248 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7468 | 0.060 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 12602 | 0.050 |
Why?
|
Cohort Studies | 5 | 2023 | 41317 | 0.050 |
Why?
|
Molecular Targeted Therapy | 2 | 2024 | 2805 | 0.050 |
Why?
|
Interleukin-7 | 1 | 2022 | 142 | 0.050 |
Why?
|
Transcription Factors | 1 | 2022 | 12100 | 0.050 |
Why?
|
Lower Extremity | 2 | 2020 | 1196 | 0.050 |
Why?
|
Tennessee | 1 | 2021 | 119 | 0.050 |
Why?
|
Administration, Intravesical | 1 | 2021 | 92 | 0.050 |
Why?
|
Respiration, Artificial | 2 | 2024 | 2623 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-fos | 1 | 2024 | 586 | 0.050 |
Why?
|
Treatment Outcome | 6 | 2024 | 64947 | 0.050 |
Why?
|
Medical Oncology | 2 | 2024 | 2321 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2020 | 5797 | 0.050 |
Why?
|
Gentamicins | 1 | 2021 | 252 | 0.050 |
Why?
|
Censuses | 1 | 2022 | 201 | 0.050 |
Why?
|
Urinary Catheterization | 1 | 2021 | 200 | 0.050 |
Why?
|
Aminolevulinic Acid | 1 | 2021 | 142 | 0.040 |
Why?
|
Cause of Death | 2 | 2022 | 3723 | 0.040 |
Why?
|
Hospitals, University | 1 | 2021 | 568 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2024 | 612 | 0.040 |
Why?
|
Vaccination | 2 | 2021 | 3360 | 0.040 |
Why?
|
Gene Fusion | 1 | 2022 | 354 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 635 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 11341 | 0.040 |
Why?
|
Calcaneus | 1 | 2020 | 141 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 558 | 0.040 |
Why?
|
Epidemiologic Studies | 1 | 2021 | 670 | 0.040 |
Why?
|
Hyaluronic Acid | 1 | 2021 | 482 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2021 | 859 | 0.040 |
Why?
|
Genomics | 2 | 2024 | 5790 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2024 | 8498 | 0.030 |
Why?
|
Health Facilities | 1 | 2022 | 578 | 0.030 |
Why?
|
Tumor Burden | 1 | 2022 | 1897 | 0.030 |
Why?
|
Photosensitizing Agents | 1 | 2021 | 616 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2023 | 1765 | 0.030 |
Why?
|
Acetabulum | 1 | 2020 | 541 | 0.030 |
Why?
|
Foot | 1 | 2020 | 573 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2021 | 58947 | 0.030 |
Why?
|
Adolescent | 5 | 2021 | 87747 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2024 | 15827 | 0.030 |
Why?
|
Intestinal Obstruction | 1 | 2018 | 435 | 0.030 |
Why?
|
Risk Factors | 4 | 2022 | 74269 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2023 | 2058 | 0.030 |
Why?
|
Heart Failure | 1 | 2018 | 11835 | 0.030 |
Why?
|
Young Adult | 4 | 2021 | 58673 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9274 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 1 | 2024 | 6545 | 0.030 |
Why?
|
Prospective Studies | 3 | 2022 | 54263 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1675 | 0.030 |
Why?
|
Accidental Falls | 1 | 2020 | 1054 | 0.030 |
Why?
|
Angiogenesis Inhibitors | 1 | 2022 | 2047 | 0.030 |
Why?
|
Epigenesis, Genetic | 1 | 2024 | 3758 | 0.020 |
Why?
|
Alleles | 1 | 2021 | 6900 | 0.020 |
Why?
|
Adult | 5 | 2024 | 219847 | 0.020 |
Why?
|
DNA Methylation | 1 | 2024 | 4374 | 0.020 |
Why?
|
Pyridines | 1 | 2022 | 2877 | 0.020 |
Why?
|
United States | 3 | 2023 | 72363 | 0.020 |
Why?
|
Odds Ratio | 1 | 2022 | 9712 | 0.020 |
Why?
|
Radiography | 1 | 2020 | 6965 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2020 | 25928 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2022 | 3737 | 0.020 |
Why?
|
Databases, Factual | 1 | 2024 | 8018 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2022 | 4554 | 0.020 |
Why?
|
Anticoagulants | 1 | 2023 | 4896 | 0.020 |
Why?
|
Smoking | 1 | 2024 | 9070 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2024 | 11480 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2021 | 3967 | 0.020 |
Why?
|
Hemorrhage | 1 | 2018 | 3604 | 0.020 |
Why?
|
Phenotype | 1 | 2023 | 16543 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2022 | 5640 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 6948 | 0.020 |
Why?
|
Prognosis | 1 | 2023 | 29636 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 20048 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 29950 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2018 | 11891 | 0.010 |
Why?
|
Concepts
(157)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(67)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_